NASDAQ:NGM

NGM Biopharmaceuticals News Headlines

$26.15
+0.08 (+0.31 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$25.36
Now: $26.15
$26.45
50-Day Range
$24.43
MA: $28.06
$31.93
52-Week Range
$14.93
Now: $26.15
$32.12
Volume74,449 shs
Average Volume294,161 shs
Market Capitalization$2.01 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.97

Headlines

NGM Biopharmaceuticals (NASDAQ NGM) News Headlines Today

SourceHeadline
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Insider Sells $616,250.00 in StockNGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Insider Sells $616,250.00 in Stock
americanbankingnews.com - April 13 at 7:50 PM
Cancer Anorexia Market Anticipated to Witness a Modest Growth at a CAGR of 10.92% During the Study Period 2018-2030 in the 7MM, Estimates DelveInsightCancer Anorexia Market Anticipated to Witness a Modest Growth at a CAGR of 10.92% During the Study Period 2018-2030 in the 7MM, Estimates DelveInsight
finanznachrichten.de - April 12 at 10:42 PM
Global Cancer Anorexia Market Outlook to 2030: Epidemiology, Drugs, Unmet Needs, Pipeline & Development Activities, CompetitionGlobal Cancer Anorexia Market Outlook to 2030: Epidemiology, Drugs, Unmet Needs, Pipeline & Development Activities, Competition
finance.yahoo.com - April 12 at 10:42 PM
NGM Biopharmaceuticals (NASDAQ:NGM) Shares Gap Down to $25.43NGM Biopharmaceuticals (NASDAQ:NGM) Shares Gap Down to $25.43
americanbankingnews.com - April 12 at 12:36 PM
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Expected to Post Earnings of -$0.48 Per ShareNGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Expected to Post Earnings of -$0.48 Per Share
americanbankingnews.com - April 1 at 8:16 PM
NGM Biopharmaceuticals (NASDAQ:NGM)  Shares Down 6.8% NGM Biopharmaceuticals (NASDAQ:NGM) Shares Down 6.8%
americanbankingnews.com - March 26 at 1:50 PM
Strength Seen in NGM Biopharmaceuticals (NGM): Can Its 6.7% Jump Turn into More Strength?Strength Seen in NGM Biopharmaceuticals (NGM): Can Its 6.7% Jump Turn into More Strength?
finance.yahoo.com - March 26 at 1:17 PM
Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In GrowthCompanies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
finance.yahoo.com - March 15 at 1:48 PM
Gemini Therapeutics: Precision Medicine Company Focused On Dry AMDGemini Therapeutics: Precision Medicine Company Focused On Dry AMD
seekingalpha.com - March 5 at 12:59 AM
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue EstimatesNGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
finance.yahoo.com - March 4 at 10:48 PM
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial ResultsNGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 4 at 5:45 PM
NGM Bio to Present at the Cowen 41st Annual Health Care ConferenceNGM Bio to Present at the Cowen 41st Annual Health Care Conference
finance.yahoo.com - February 25 at 8:11 AM
How this cancer-fighting company from China quietly landed as the Bay Areas latest biotech IPOHow this cancer-fighting company from China quietly landed as the Bay Area's latest biotech IPO
bizjournals.com - February 9 at 10:26 PM
Geographic Atrophy Pipeline Report 2021: Therapeutic Evaluation, Drug Profiles, Unmet Needs, Prominent CompaniesGeographic Atrophy Pipeline Report 2021: Therapeutic Evaluation, Drug Profiles, Unmet Needs, Prominent Companies
benzinga.com - February 9 at 10:26 PM
NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual EditionNGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition
finance.yahoo.com - February 9 at 8:28 AM
Could The NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Ownership Structure Tell Us Something Useful?Could The NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Ownership Structure Tell Us Something Useful?
finance.yahoo.com - January 14 at 4:23 PM
NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and OncologyNGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology
finance.yahoo.com - January 13 at 5:38 AM
NGM Biopharmaceuticals Inc Registered Shs Strong BuyNGM Biopharmaceuticals Inc Registered Shs Strong Buy
markets.businessinsider.com - January 10 at 12:53 AM
NGM Bio prices $125M share offeringNGM Bio prices $125M share offering
seekingalpha.com - January 7 at 5:48 PM
NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common StockNGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock
finance.yahoo.com - January 5 at 10:54 PM
NGM Bio Announces Proposed Offering of Common StockNGM Bio Announces Proposed Offering of Common Stock
finance.yahoo.com - January 4 at 8:20 PM
NGM Jan 2021 20.000 callNGM Jan 2021 20.000 call
au.finance.yahoo.com - December 24 at 10:54 PM
NGM Jan 2021 15.000 callNGM Jan 2021 15.000 call
au.finance.yahoo.com - December 24 at 12:51 AM
Is NGM A Good Stock To Buy Now?Is NGM A Good Stock To Buy Now?
finance.yahoo.com - December 12 at 5:17 AM
NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid TumorsNGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors
finance.yahoo.com - December 9 at 6:10 PM
NGM Nov 2020 20.000 callNGM Nov 2020 20.000 call
au.finance.yahoo.com - November 20 at 6:59 PM
NGM to Host Virtual R&D Day on December 9, 2020NGM to Host Virtual R&D Day on December 9, 2020
feeds.benzinga.com - November 16 at 12:44 PM
Analyst Estimates: Heres What Brokers Think Of NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) After Its Third-Quarter ReportAnalyst Estimates: Here's What Brokers Think Of NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) After Its Third-Quarter Report
finance.yahoo.com - November 15 at 1:11 PM
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 VirtualNGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual
finance.yahoo.com - November 13 at 9:39 AM
NGM Biopharmaceuticals EPS misses by $0.04, beats on revenueNGM Biopharmaceuticals EPS misses by $0.04, beats on revenue
seekingalpha.com - November 12 at 6:58 PM
NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial ResultsNGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results
finance.yahoo.com - November 12 at 6:58 PM
NGM Bio to Present at Three Upcoming Investor ConferencesNGM Bio to Present at Three Upcoming Investor Conferences
finance.yahoo.com - November 11 at 9:38 AM
If You Had Bought NGM Biopharmaceuticals (NASDAQ:NGM) Shares A Year Ago Youd Have Earned 46% ReturnsIf You Had Bought NGM Biopharmaceuticals (NASDAQ:NGM) Shares A Year Ago You'd Have Earned 46% Returns
finance.yahoo.com - November 9 at 12:36 PM
NGM Bio to Present Safety and Pharmacokinetics Data from Phase 1 Study of NGM621 in Patients with Geographic Atrophy at American Academy of Ophthalmology (AAO) 2020 VirtualNGM Bio to Present Safety and Pharmacokinetics Data from Phase 1 Study of NGM621 in Patients with Geographic Atrophy at American Academy of Ophthalmology (AAO) 2020 Virtual
finance.yahoo.com - November 5 at 9:25 AM
NGM Bio Announces Multiple Aldafermin Presentations at Upcoming AASLD The Liver Meeting®, including Late-Breaking Oral Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASHNGM Bio Announces Multiple Aldafermin Presentations at Upcoming AASLD The Liver Meeting®, including Late-Breaking Oral Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH
finance.yahoo.com - November 4 at 8:32 AM
Earnings Preview: NGM Biopharmaceuticals (NGM) Q3 Earnings Expected to DeclineEarnings Preview: NGM Biopharmaceuticals (NGM) Q3 Earnings Expected to Decline
finance.yahoo.com - November 3 at 2:21 PM
Ive owned, improved, and sold hundreds of businesses successfully. Here are the 6 areas you should be focusing on if you want to sell your business at its maximum value.I've owned, improved, and sold hundreds of businesses successfully. Here are the 6 areas you should be focusing on if you want to sell your business at its maximum value.
msn.com - October 27 at 12:47 PM
NGM expands oncology portfolio with first immuno-oncology development candidateNGM expands oncology portfolio with first immuno-oncology development candidate
seekingalpha.com - October 19 at 1:46 PM
NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4
markets.businessinsider.com - October 19 at 8:46 AM
Global Primary Sclerosing Cholangitis Market 2017-2020 & 2030 Featuring Gilead Sciences, HighTide Biopharma, NGM Biopharmaceuticals, Intercept Pharmaceuticals, Dr Falk PharmaGlobal Primary Sclerosing Cholangitis Market 2017-2020 & 2030 Featuring Gilead Sciences, HighTide Biopharma, NGM Biopharmaceuticals, Intercept Pharmaceuticals, Dr Falk Pharma
markets.businessinsider.com - October 14 at 4:25 AM
Surrozen Expands Board of Directors with Appointment of David J. Woodhouse, Ph.D.Surrozen Expands Board of Directors with Appointment of David J. Woodhouse, Ph.D.
feeds.benzinga.com - September 25 at 7:30 AM
NGM Biopharmaceuticals (NGM) Investor Presentation - SlideshowNGM Biopharmaceuticals (NGM) Investor Presentation - Slideshow
seekingalpha.com - August 31 at 3:33 PM
NGM Bios aldafermin shows positive effect in NASH patients with advanced diseaseNGM Bio's aldafermin shows positive effect in NASH patients with advanced disease
seekingalpha.com - August 31 at 10:44 AM
NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 StudyNGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study
finance.yahoo.com - August 29 at 7:28 AM
NGM Bio a stock to watch ahead of key NASH presentationNGM Bio a stock to watch ahead of key NASH presentation
seekingalpha.com - August 18 at 1:40 PM
NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 Study (Cohort 4) of  Aldafermin in Patients with NASH at The Digital International Liver Congress™ (ILC) 2020NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH at The Digital International Liver Congress™ (ILC) 2020
finance.yahoo.com - August 18 at 8:39 AM
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue EstimatesNGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 12 at 10:34 PM
NGM Biopharmaceuticals EPS misses by $0.04, misses on revenueNGM Biopharmaceuticals EPS misses by $0.04, misses on revenue
seekingalpha.com - August 12 at 5:34 PM
NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial ResultsNGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results
finance.yahoo.com - August 12 at 5:34 PM
Were Not Very Worried About NGM Biopharmaceuticals (NASDAQ:NGM) Cash Burn RateWe're Not Very Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
finance.yahoo.com - August 11 at 4:06 PM
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.